MAXIPIME

Compare MAXIPIME  to:
Compare
Compare

Generic Name for MAXIPIME

Cefepime (as HCl) 500mg, 1g, 2g; pwd for IV infusion or IM inj after reconstitution.

Legal Classification:

Rx

Pharmacological Class for MAXIPIME

Cephalosporin.

Manufacturer of MAXIPIME

Elan Pharmaceuticals

Indications for MAXIPIME

Susceptible infections, including moderate-to-severe pneumonia, uncomplicated skin and skin structure infections, complicated and uncomplicated urinary tract infections (UTIs) including pyelonephritis, complicated intraabdominal in adults (w. metronidazole). Empiric therapy in febrile neutropenia.

Adult dose for MAXIPIME

When giving IV, infuse over 30 minutes. Pneumonia: 1–2g IV every 12 hrs for 10 days. Skin and skin structures, severe UTIs: 2g IV every 12 hrs for 10 days. Mild-to-moderate UTIs: 500mg–1g IV or IM every 12 hrs for 7–10 days (IM only for UTIs caused by E. coli). Intraabdominal (use w. metronidazole): 2g IV every 12 hrs for 7–10 days. Febrile neutropenia: 2g IV every 8 hrs for 7 days or until neutropenia resolves. CrCl ≤60mL/min: reduce dose; see literature. Hemodialysis: repeat initial dose after each session. Continuous ambulatory peritoneal dialysis: give usual doses at 48-hour intervals.

Children's dosing for MAXIPIME

<2months: not recommended. Not for use in serious infection when pathogen is or may be H. influenzae type b. 2months–16yrs (≤40kg): 50mg/kg per dose, given every 12 hrs; do not exceed recommended adult dose. Severe UTIs, pneumonia, skin and skin structure: give IV for 10 days. Mild-to-moderate UTIs: give IV or IM for 7–10 days (IM only for UTIs caused by E. coli). Febrile neutropenia: give IV every 8 hours for 7 days or until neutropenia resolves.

Contraindications for MAXIPIME

Penicillin or other β-lactam allergy.

Precautions for MAXIPIME

Renal impairment. Renal or hepatic dysfunction, poor nutritional state, prolonged antimicrobial therapy: monitor prothrombin time. History of GI disease (esp. colitis). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.

Interactions for MAXIPIME

Aminoglycosides may potentiate oto- or nephrotoxicity. Possible nephrotoxicity with diuretics (eg, furosemide). May cause false (+) Coomb's, Clinitest.

Adverse Reactions for MAXIPIME

Local reactions (eg, pain, phlebitis, inflammation), rash, GI disturbances, pruritus, fever, headache, seizures, encephalopathy, blood dyscrasias, anemia, renal dysfunction, others.

How is MAXIPIME supplied?

Vials (500mg, 1g, 2g)—10

Related Disease:

Infections, bacterial~systemic antiinfectives
Pneumonia

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.